Denzlingen, Germany

Jorgen Kleinschroth


Average Co-Inventor Count = 7.5

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 1987-1988

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jorgen Kleinschroth: Innovator in Pharmaceutical Chemistry

Introduction

Jorgen Kleinschroth is a notable inventor based in Denzlingen, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that address blood vessel diseases. With a total of 2 patents, his work has the potential to impact cardiovascular health positively.

Latest Patents

Kleinschroth's latest patents include innovative compounds such as 1,6-naphthyridine derivatives. These derivatives are designed to treat blood vessel diseases and are characterized by a complex formula that includes various substituents. The invention provides processes for the preparation of these derivatives, pharmaceutical compositions containing them, and methods for their use. Another significant patent involves 4-alkoxy-pyrido[2,3-d]pyrimidine derivatives, which are indicated for treating cerebral, cardiac, and peripheral vascular diseases. These compounds are valuable agents in combating cardiovascular mortality due to their vasospasmolytic effects.

Career Highlights

Throughout his career, Jorgen Kleinschroth has worked with reputable companies, including Goedecke Aktiengesellschaft and Godecke Aktiengesellschaft. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.

Collaborations

Kleinschroth has collaborated with notable professionals in his field, including Karl Mannhardt and Johannes Hartenstein. These collaborations have likely enriched his research and development efforts.

Conclusion

Jorgen Kleinschroth's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an innovator in the field. His work continues to pave the way for advancements in treatments for cardiovascular diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…